GENE EDITING SOLUTIONS

Delivering the Next Evolution of Healthcare

Recombinetics is a recognized leader in animal gene editing and associated applied technologies for biomedical research, regenerative medicine and animal agriculture.

We leverage our proprietary gene editing platform to commercialize and deploy technologies through four subsidiaries that pivotally impact human health and longevity and add value to farm animals.

Gene Editing

FACING THE FACTS

113,000

people are currently on the U.S. transplant list—83% are waiting for a kidney
Mouse DNA icon

90%

of all clinical trials fail
Skinny cow icon

1.5 BILLION

smallholders are raising unproductive animals
Girls getting better
our work

Groundbreaking Technology for Life-Changing Solutions

Recombinetics has the most experienced and reliable animal gene-editing team on the planet developing solutions through four customer-facing subsidiaries focused on three key areas:

Regenerative medicine

Transforming Tissue Regeneration

We are engineering biologics initially focused on Hernia repair. Sarxion Biologics’ ECM material has improved integration and healing.

preclinical research

Bringing Precision Medicine to Brain Tumors

We are a clinical-stage neuro-oncology therapeutics company bringing precision medicine to patients with Glioblastoma (GBM) and Neurofibromatosis Types 1 and 2 (NF1 and NF2).

precision breeding

Producing Healthier, Happier Animals and More Sustainable Farming

We use state-of-the-art breeding methods to precisely deliver traits that improve the health, welfare and sustainability of food animals to feed a hungry world while protecting the environment.

notable news

Recombinetics Merges with Makana Therapeutics to Accelerate Transplantation

Makana Therapeutics has become Recombinetics Inc.’s newest subsidiary and is exclusively focused on addressing the organ shortage crisis. Recombinetics and Makana have expertise and strong, synergistic intellectual property positions in clinical organ transplantation, genetic engineering, reproductive technology, and xenotransplantation. The merger allows our scientists to focus on and commercialize a pipeline of transplantable cells, tissues, and organs for human patient use.

Transplant surgery

Your investment can help us change the world.

Reach out today for information on how you can make a difference.

Contact Us